allo HCT

PROCEDURE2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

HIVHematologic MalignanciesImmune System DiseasesLymphoproliferative DisordersPeripheral T-cell Lymphomas

Phase 1

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

RecruitingNCT05470491

National Cancer Institute (NCI)HIV, Hematologic Malignancies

Start: 2023-01-26End: 2028-07-30Target: 265Updated: 2026-09-08

Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Active, not recruitingNCT03922724

National Cancer Institute (NCI)Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases

Start: 2019-04-18End: 2030-10-31Updated: 2026-09-11

Related Papers

Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant

Blood Advances2026-07-17

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.

2026-04-23

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Blood2024-11-05